 In 1988, a monoclonal antibody called infliximab was discovered at New York University's School of Medicine.Infliximab works by binding to TNF, stopping its inflammatory effects.It was initially used for the treatment of Crohn's disease and it became the first FDA approved TNF inhibitor in 1998.